Menu
Back to Journals » Infection and Drug Resistance » Volume 5
Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients
Authors Miceli, Chandrasekar P
Received 16 November 2011
Accepted for publication 2 December 2011
Published 11 January 2012 Volume 2012:5 Pages 9—16
DOI https://doi.org/10.2147/IDR.S22587
Review by Single anonymous peer review
Peer reviewer comments 3
Marisa H Miceli1, Pranatharthi Chandrasekar2
1Oakwood Hospital and Medical Center, Dearborn, 2Division of Infectious Diseases, Wayne State University School of Medicine, Detroit, MI, USA
Abstract: Liposomal amphotericin B is a "true" liposomal formulation of amphotericin B with greatly reduced nephrotoxicity and minimal infusion-related toxicity. This broad spectrum polyene is well tolerated and effective against most invasive fungal infections. In view of the current limitations on diagnostic capability of invasive fungal infections, most clinicians are often compelled to use antifungal drugs in an empiric manner; liposomal amphotericin B continues to play an important role in the empiric management of invasive fungal infections, despite the recent availability of several other drugs in the azole and echinocandin classes.
Keywords: invasive fungal infections, immunocompromised hosts, empiric therapy, polyenes, efficacy and safety
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.